Who is sponsoring NCT05837052?

NCT05837052 is sponsored by Zhejiang University.

What drugs are being tested in NCT05837052?

Interventions in NCT05837052: serplulimab plus chemotherapy as conversion treatment.

What condition does NCT05837052 study?

NCT05837052 studies Unresectable Lung Non-Small Cell Carcinoma.

Is NCT05837052 still recruiting?

NCT05837052 is currently recruiting now. Last updated 17 July 2023.

Last reviewed 2023-07-17 · How we verify

NCT05837052

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Recruiting now Phase 2 Last updated 17 July 2023

What this trial tests

Phase 2 trial testing serplulimab plus chemotherapy as conversion treatment in Unresectable Lung Non-Small Cell Carcinoma in 49 participants. Currently enrolling.

Timeline

15 May 2023

Primary endpoint
30 June 2025

30 December 2026

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	15 May 2023
Primary completion	30 June 2025
Estimated completion	30 December 2026
Sites	1 location across China

Drugs / interventions tested

serplulimab plus chemotherapy as conversion treatment

Conditions studied

Unresectable Lung Non-Small Cell Carcinoma — all drugs for Unresectable Lung Non-Small Cell Carcinoma →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Unresectable Lung Non-Small Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Oligometastatic NSCLC: Current Perspectives and Future Challenges.
Torresan S, Costa J, Zanchetta C, De Marchi L, et al · · 2025 · cited 6× · PMID 39996875 · DOI 10.3390/curroncol32020075

Verify or expand the search:

Other recruiting trials for Unresectable Lung Non-Small Cell Carcinoma

Currently open trials in the same condition.

NCT06073431 — LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia · recruiting
NCT05098210 — Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg · Phase 1 · recruiting
NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05166616 — Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer · Phase 1 · active not recruiting
NCT05136846 — Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05837052 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 17 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05837052.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing